MHY2013

MHY2013 is a potent small molecule peroxisome proliferator-activated receptor (PPAR) pan-agonist that targets all three isoforms: PPARα, PPARβ/δ, and PPARγ. It was synthesized and characterized by researchers at Pusan National University for the treatment of metabolic and fibrotic disorders. In preclinical models, MHY2013 has demonstrated significant anti-fibrotic and anti-inflammatory effects in the kidneys, specifically reducing tubule damage, myofibroblast activation, and pro-inflammatory cytokine production. Its mechanism of action involves the direct inhibition of TGF-β/SMAD signaling in fibroblasts via PPARγ and the suppression of NF-κB activation in epithelial cells via PPARβ/δ.